Triple receptor agonist — simultaneously activates GLP-1, GIP, and glucagon receptors — the first compound to target all three. Clinical data show up to 24 % weight loss after 48 weeks and reduction of liver fat by over 82 %, placing Retatrutide among the most effective for obesity and metabolic disorders.
For research use only.
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly. It is the first compound designed to simultaneously activate three incretin and metabolic hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon.
Unlike the dual agonist Tirzepatide (GLP-1/GIP) or the mono-agonist Semaglutide (GLP-1), Retatrutide adds glucagon-receptor activation, which in studies is associated with additional increases in energy expenditure, lipolysis and reduced liver fat. In the literature, this combination of three mechanisms is described as the basis of a stronger metabolic effect than a single or dual agonist.
Shelf life under recommended conditions: up to the date indicated on the packaging (up to 24 months).
Avoid temperature fluctuations.